新股消息 | 滨会生物拟港股IPO 中国证监会要求补充说明迁移相关业务具体情况等

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for five companies, including Wuhan Binhui Biotechnology Co., Ltd., which is seeking to list on the Hong Kong Stock Exchange [1][2] Group 1: Regulatory Requirements - The CSRC has requested Binhui Biotechnology to clarify the pricing basis for equity transfers involving new shareholders within 12 months prior to the overseas listing application, including reasons for pricing differences and tax payment status of transferors [1][2] - The company must provide updates on the business duration and renewal status of its shareholder Longpan Biopharmaceutical, ensuring that these matters do not adversely affect the listing [1][2] - Binhui Biotechnology is required to outline measures taken to protect the rights of long-missing individual shareholder Qian Xiangfeng, along with clear evidence of these actions [1][2] Group 2: Company Overview - Binhui Biotechnology is a biopharmaceutical company focused on oncolytic virus therapy, aiming to innovate cancer immunotherapy through the discovery, development, and commercialization of treatments that outperform standard therapies in efficacy and safety [2] - The company is led by Dr. Liu Binlei, who has over 30 years of expertise in tumor immunology and oncolytic virology [2]